Longitudinal changes in 18F-THK5351 positron emission tomography in corticobasal syndrome
M. Ezura
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
These authors contributed equally to this work.
Search for more papers by this authorCorresponding Author
A. Kikuchi
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
These authors contributed equally to this work.
Correspondence: A. Kikuchi, Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan (tel.: +81-22-717-7189; fax: +81-22-717-7192; e-mail: [email protected])
and
N. Okamura, Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan (tel.: +81-22-290-8721; fax: +81-22-290-8748; e-mail: [email protected]).
Search for more papers by this authorA. Ishiki
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
These authors contributed equally to this work.
Search for more papers by this authorCorresponding Author
N. Okamura
Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
These authors contributed equally to this work.
Correspondence: A. Kikuchi, Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan (tel.: +81-22-717-7189; fax: +81-22-717-7192; e-mail: [email protected])
and
N. Okamura, Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan (tel.: +81-22-290-8721; fax: +81-22-290-8748; e-mail: [email protected]).
Search for more papers by this authorT. Hasegawa
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorR. Harada
Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorS. Watanuki
Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorY. Funaki
Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorK. Hiraoka
Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorT. Baba
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorN. Sugeno
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorR. Oshima
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorS. Yoshida
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorJ. Kobayashi
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorM. Kobayashi
Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Search for more papers by this authorO. Tano
Department of Neurology, Sendai Medical Center, Sendai, Japan
Search for more papers by this authorI. Nakashima
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Search for more papers by this authorS. Mugikura
Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorR. Iwata
Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorY. Taki
Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Search for more papers by this authorK. Furukawa
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Division of Community of Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Search for more papers by this authorH. Arai
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Search for more papers by this authorS. Furumoto
Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorM. Tashiro
Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorK. Yanai
Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorY. Kudo
Division of Neuroimaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Search for more papers by this authorA. Takeda
Department of Neurology, National Hospital Organization, Sendai Nishitaga Hospital, Sendai, Japan
Search for more papers by this authorM. Aoki
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorM. Ezura
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
These authors contributed equally to this work.
Search for more papers by this authorCorresponding Author
A. Kikuchi
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
These authors contributed equally to this work.
Correspondence: A. Kikuchi, Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan (tel.: +81-22-717-7189; fax: +81-22-717-7192; e-mail: [email protected])
and
N. Okamura, Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan (tel.: +81-22-290-8721; fax: +81-22-290-8748; e-mail: [email protected]).
Search for more papers by this authorA. Ishiki
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
These authors contributed equally to this work.
Search for more papers by this authorCorresponding Author
N. Okamura
Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
These authors contributed equally to this work.
Correspondence: A. Kikuchi, Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan (tel.: +81-22-717-7189; fax: +81-22-717-7192; e-mail: [email protected])
and
N. Okamura, Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan (tel.: +81-22-290-8721; fax: +81-22-290-8748; e-mail: [email protected]).
Search for more papers by this authorT. Hasegawa
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorR. Harada
Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorS. Watanuki
Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorY. Funaki
Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorK. Hiraoka
Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorT. Baba
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorN. Sugeno
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorR. Oshima
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorS. Yoshida
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorJ. Kobayashi
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorM. Kobayashi
Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Search for more papers by this authorO. Tano
Department of Neurology, Sendai Medical Center, Sendai, Japan
Search for more papers by this authorI. Nakashima
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Search for more papers by this authorS. Mugikura
Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorR. Iwata
Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorY. Taki
Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Search for more papers by this authorK. Furukawa
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Division of Community of Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
Search for more papers by this authorH. Arai
Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Search for more papers by this authorS. Furumoto
Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorM. Tashiro
Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Search for more papers by this authorK. Yanai
Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorY. Kudo
Division of Neuroimaging, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
Search for more papers by this authorA. Takeda
Department of Neurology, National Hospital Organization, Sendai Nishitaga Hospital, Sendai, Japan
Search for more papers by this authorM. Aoki
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for more papers by this authorAbstract
Background and purpose
Corticobasal syndrome (CBS) is pathologically characterized by tau deposits in neuronal and glial cells and by reactive astrogliosis. In several neurodegenerative disorders, 18F-THK5351 has been observed to bind to reactive astrocytes expressing monoamine oxidase B. In this study, the aim was to investigate the progression of disease-related pathology in the brains of patients with CBS using positron emission tomography with 18F-THK5351.
Methods
Baseline and 1-year follow-up imaging were acquired using magnetic resonance imaging and positron emission tomography with 18F-THK5351 in 10 subjects: five patients with CBS and five age-matched normal controls (NCs).
Results
The 1-year follow-up scan images revealed that 18F-THK5351 retention had significantly increased in the superior parietal gyrus of the patients with CBS compared with the NCs. The median increases in 18F-THK5351 accumulation in the patients with CBS were 6.53% in the superior parietal gyrus, 4.34% in the precentral gyrus and 4.33% in the postcentral gyrus. In contrast, there was no significant increase in the regional 18F-THK5351 retention in the NCs.
Conclusions
Longitudinal increases in 18F-THK5351 binding can be detected over a short interval in the cortical sites of patients with CBS. A monoamine oxidase B binding radiotracer could be useful in monitoring the progression of astrogliosis in CBS.
Disclosure of conflicts of interest
N.O., S.F. and Y.K. received research grants from GE Healthcare. Y.K. received research grants from Sumitomo Electric Industries. N.O. and Y.K. own stock in Clino Ltd.
References
- 1Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18: 20–33.
- 2Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112: 1171–1192.
- 3Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094–1108.
- 4Kikuchi A, Okamura N, Hasegawa T, et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 2016; 87: 2309–2316.
- 5Cho H, Baek MS, Choi JY, et al. (18)F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology 2017; 89: 1170–1178.
- 6Smith R, Scholl M, Widner H, et al. In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Neurology 2017; 89: 845–853.
- 7Niccolini F, Wilson H, Hirschbichler S, et al. Disease-related patterns of in vivo pathology in corticobasal syndrome. Eur J Nucl Med Mol Imaging 2018; 45: 2413–2425.
- 8Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry 2012; 83: 405–410.
- 9Tong J, Meyer JH, Furukawa Y, et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 2013; 33: 863–871.
- 10Kouri N, Murray ME, Hassan A, et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134: 3264–3275.
- 11Tsuboi Y, Josephs KA, Boeve BF, et al. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord 2005; 20: 982–988.
- 12Perez-Soriano A, Matarazzo M, Vafai N, et al. PBB3 binding in a patient with corticobasal syndrome. Mov Disord 2018; 33: 1359–1360.
- 13Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787–800.
- 14Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 2016; 12: 1116–1124.
- 15Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 2016; 4: 58.
- 16Hostetler ED, Walji AM, Zeng Z, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med 2016; 57: 1599–1606.
- 17Hansen AK, Knudsen K, Lillethorup TP, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Brain 2016; 139: 2039–2049.
- 18Harada R, Ishiki A, Kai H, et al. Correlations of (18)F-THK5351 PET with postmortem burden of tau and astrogliosis in Alzheimer disease. J Nucl Med 2018; 59: 671–674.
- 19Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience 1991; 45: 1–12.
- 20Ng KP, Pascoal TA, Mathotaarachchi S, et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther 2017; 9: 25.
- 21Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117: 1183–1196.
